Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Ipca Laboratories Limited, a pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, CIS, and Australasia. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company also provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, hematology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. It also exports its products worldwide. The company was incorporated in 1949 and is based in Mumbai, India.

Revenue projections:

Revenue projections for IPCALAB
Revenue projections for IPCALAB

Investors may be wary of IPCALAB as its revenues are expected to fall below the prior year's levels. A revenue decrease often leads to concerns about profitability, as it is likely to affect the company's bottom line, prompting investors to take a more cautious approach.

Financial Ratios:

currentRatio 0.000000
forwardPE 26.870306
debtToEquity 14.425000
earningsGrowth 0.236000
revenueGrowth 0.066000
grossMargins 0.669450
operatingMargins 0.177960
trailingEps 35.810000
forwardEps 53.955470

IPCALAB's Forward PE being in a reasonable range suggests the stock is fairly priced based on its earnings. The stock isn't overpriced, leaving room for growth, making it an attractive investment for those seeking opportunities for future value appreciation.
IPCALAB's low Debt-to-Equity ratio indicates that the company isn't heavily dependent on debt financing. This lower leverage reduces financial risk and enhances stability, showing that IPCALAB is well-positioned to manage its obligations without the burden of excessive debt.
Ipca Laboratories Limited's forward EPS surpasses its trailing EPS, indicating that the company is expected to be more profitable in the current financial year. This reflects growing confidence in Ipca Laboratories Limited's earnings potential, suggesting stronger financial performance compared to the previous year.

Price projections:

Price projections for IPCALAB
Price projections for IPCALAB

Ipca Laboratories Limited's price projections have gradually risen, indicating growing confidence in the company's prospects. This upward trend suggests that analysts expect Ipca Laboratories Limited to continue performing well in the future.

Insider Transactions:

Insider Transactions for IPCALAB
Insider Transactions for IPCALAB


Ipca Laboratories Limited saw 2 transactions in which shares were sold with market price at 1456.75.During the period under consideration, no sell transactions took place.The higher number of buys versus sells near IPCALAB's current price suggests optimism among investors. This buying trend could be interpreted as a sign that the market expects favorable outcomes for the stock in the near future.

Recommendation changes over time:

Recommendations trend for IPCALAB
Recommendations trend for IPCALAB


Analysts have been favoring IPCALAB with a buy bias recently, signaling a promising investment opportunity. This optimistic outlook may attract more investors, positioning IPCALAB as a desirable option for those seeking to invest their money in a stable, profitable company with strong growth potential.